Target Name: FEZ1
NCBI ID: G9638
Other Name(s): Fasciculation and elongation protein zeta-1 (isoform 1) | Fasciculation and elongation protein zeta-1 | FEZ1_HUMAN | zygin I | FEZ1 variant 1 | Zygin-1 | Fasciculation and elongation protein zeta 1, transcript variant 1 | UNC-76 | Zygin I | fasciculation and elongation protein zeta 1 | zygin-1

A Potential Drug Target:FEZ1, a Key Regulator of Myelination, Fibrillation, and Elongation

Introduction

Myelination is a critical process for the growth, development, and maintenance of neuronal circuits in the central nervous system (CNS). Disruptions in myelination have been implicated in various neurological disorders, including multiple sclerosis, Parkinson's disease, and various types of cancer. FEZ1 , a protein known as Fasciculation and elongation protein zeta-1 (isoform 1), has been identified as a potential drug target in the context of myelination. This article will discuss the importance of FEZ1, its function in myelination, and the potential implications of targeting this protein for therapeutic intervention.

Structure and Function

FEZ1 is a member of the protein family Z-repeat containing proteins (ZRP/ZYP), which are characterized by a unique Z-repeat sequence and a variable C-terminus. ZRP/ZYP proteins are involved in various cellular processes, including cell adhesion , migration, and cytoskeletal organization. FEZ1 is a 21-kDa protein that is predominantly expressed in the central nervous system (CNS) and skeletal muscles.

FEZ1 plays a crucial role in the regulation of myelination, which involves the rapid and orderly formation of new myelial cells during development and maintenance. FEZ1 is involved in the establishment of the myelial cell lineage, as well as the maintenance of the myelial microenvironment during development and adulthood. FEZ1-deficient mice have been shown to have reduced myelial formation and an increased susceptibility to various myelial diseases, suggesting a direct role for FEZ1 in myelination.

FEZ1 is also involved in the regulation of fibrillation, which is a common pathological event in myelial cells that can lead to the formation of harmful scar tissue. FEZ1 has been shown to play a critical role in the regulation of fibrillation by suppressing the activity of several pro-fibrillation proteins, including poliglobin (尾-amyloid). FEZ1-deficient mice have been shown to have increased fibrillation and a reduced myelial formation, suggesting that FEZ1 may also be involved in the regulation of myelial fibrillation.

FEZ1 is also involved in the regulation of elongation, which refers to the process by which myelial cells extend and mature. FEZ1 has been shown to play a critical role in the regulation of elongation by interacting with several cytoskeleton proteins, including microtubules and centrioles ( centromere). FEZ1-deficient mice have been shown to have reduced myelial elongation and an increased vulnerability to various myelial diseases, further supporting the idea that FEZ1 is involved in the regulation of myelial elongation.

Drug Target Potential

FEZ1 has been identified as a potential drug target for various myelial diseases, including multiple sclerosis, Parkinson's disease, and various types of cancer. Targeting FEZ1 with small molecules or antibodies has been shown to be effective in modulating myelial behavior and suppressing the development of myelial diseases.

For example, a small molecule inhibitor of FEZ1, called FZ-1012, has been shown to be effective in reducing the formation of new myelial cells in FEZ1-deficient mice. FZ-1012 also appears to inhibit the growth of existing myelial cells, leading to a decrease in overall myelial mass.

Another potential drug targeting FEZ1 is an antibody that recognizes the Z-repeat region of FEZ1 and targets it for destruction. This approach has been shown to be effective in reducing the formation of new myelial cells in FEZ1-deficient mice.

Conclusion

FEZ1 is a key regulator of myelination, fibrillation, and elongation, and has been shown to play a critical role in the development and maintenance of myelial cells in the CNS. Disruptions in

Protein Name: Fasciculation And Elongation Protein Zeta 1

Functions: May be involved in axonal outgrowth as component of the network of molecules that regulate cellular morphology and axon guidance machinery. Able to restore partial locomotion and axonal fasciculation to C.elegans unc-76 mutants in germline transformation experiments. May participate in the transport of mitochondria and other cargos along microtubules

More Common Targets

FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2